IntelliPharmaCeutics Meets a 2012 Goal for Abuse-Deterrent Oxycodone

TORONTO, May 1, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today provided an update on its research and development activities and achievement of a goal in relation to its Rexista™ abuse-deterrent formulations for opioid and narcotic drugs.